AstraZeneca, Breast Cancer
FDA Approves AstraZeneca's Datroway For Pretreated Breast Cancer Patients
On Friday, the U.S. Food and Drug Administration (FDA) approved AstraZeneca Plc’s (NASDAQ:AZN) Datroway (datopotamab deruxtecan or Dato-DXd) for adult patients with unresectable or metastatic hormone receptor (HR)-positive,
The clearance of Datroway comes months after the companies narrowed approval plans in lung cancer and opens up a market ...
Even before the FDA's recent approval of Dato-DXd in breast cancer, analysts predicted sales of the antibody-drug conjugate ...
AstraZeneca PLC AZN shares rallied 2.39% to £110.52 Tuesday, on what proved to be an all-around great trading session for the stock market, with the FTSE 100 Index UKX rising 0.33% to 8,548.29.
A drug from AstraZeneca and Daiichi Sankyo won authorization for a form of breast cancer, the first U.S. approval for the ...
DXd, significantly improved median progression-free survival in a Phase III study but failed to do so for overall survival.
Shares of AstraZeneca PLC AZN slid 1.32% to £107.94 Monday, on what proved to be an all-around great trading session for the ...
AstraZeneca has overhauled its local management in China, replacing Michael Lai with Alex Lin as the country's general ...
Goldman Sachs analyst Rajan Sharma maintained a Buy rating on AstraZeneca (AZN – Research Report) today and set a price target of £155.58. The ...
From accelerating drug development and clinical trials to supercharging collaboration, machine learning-enhanced healthcare ...
President Trump rescinded an executive order that prompted the creation of three Medicare drug-pricing experiments ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback